In a groundbreaking development for the treatment of obstructive hypertrophic cardiomyopathy (oHCM), the Phase 3 SEQUOIA-HCM trial has demonstrated that

In a groundbreaking analysis of the STEPHFpEF programme, researchers have discovered that semaglutide, a once-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA),

In a thought-provoking presentation, Dr. Milton Packer, a renowned expert in the field of cardiology, shed light on the groundbreaking

Professor Mark Petrie from the University of Glasgow and Glasgow Royal Infirmary presented an overview of the future directions and